Posted by Michael Wonder on 11 Oct 2023
Bimekizumab for the treatment of patients with axial spondyloarthritis
11 October 2023 - NICE has published final evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment of adults with axial spondyloarthritis.
Bimekizumab is recommended as an option for the treatment of adults with active ankylosing spondylitis when conventional therapy has not worked well enough or is not tolerated, or active non‑radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C‑reactive protein or MRI) when non-steroidal anti‑inflammatory drugs, have not worked well enough or are not tolerated.
